Prior to joining PPD, Dr Dingivan spent 12 years with MedImmune, a worldwide biologics business acquired by AstraZeneca.
Dr Dingivan earned her undergraduate degree in bioengineering from the University of Pennsylvania and medical degree from Dartmouth Medical School. She trained in general surgery at Northwestern University Medical School, Department of Surgery.
Fred Eshelman, CEO of PPD, said: “Exceptional scientific, leadership and communications skills define Christine Dingivan. With her in-depth experience in clinical development, strategic operations and medical affairs gained during her long tenure with MedImmune, she will play a key role in helping us advance our clients’s products through development.”